CD200 and neoplasm: Finally, using the RNA-seq/survival data from six publicly available patient cohorts who received ICB therapy, Wang et al. demonstrated that high CD200+ CTL tumor infiltration was indicative of a favorable response to ICB therapy, regardless of tumor type.